Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.

Article Details

Citation
Copy to clipboard

Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan AJ, Macleod PM, Zivanovic MA

Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.

Br J Radiol. 1991 Sep;64(765):816-22.

PubMed ID
1717094 [ View in PubMed
]
Abstract

In a multi-centre study strontium-89 was shown to be effective in relieving bone pain from prostatic carcinoma in patients who had failed conventional therapies. Of 83 patients assessed at 3 months, following the administration of a dose of at least 1.5 MBq/kg, 75% derived benefit and 22% became pain free. Symptomatic improvement usually occurred within 6 weeks and continued for between 4 and 15 months (mean 6 months). Based on the dose estimation part of this study the recommended dose of strontium-89 is 150 MBq. Toxicity was low, provided platelet levels were above 100 x 10(9) l-1 at the time of treatment. Repeat treatments with strontium-89 may be given at intervals of not less than 3 months. Strontium-89 is administered intravenously on an out-patient basis with no special radiological protection precautions.

DrugBank Data that Cites this Article

Drugs